
Larger-format triple agonist research peptide (GLP-1/GIP/glucagon) — 40 mg vial.
Retatrutide 40 mg is not yet released for sale. Batch release, HPLC certification and third-party testing are in progress — check back shortly.
The 40 mg Retatrutide format provides double the material per vial compared to the standard 20 mg supply, aimed at laboratories running extended in-vitro characterisation of triple-receptor agonist peptides.
As with every Retatrutide vial from NXT GEN PEPTIDES, the 40 mg format is manufactured to strict laboratory standards, HPLC-characterised and independently third-party tested. Lyophilised under sterile conditions and supplied in an amber vial to preserve peptide integrity.
Retatrutide is widely investigated in laboratory environments to explore areas including:
The 40 mg format supports longer characterisation runs and larger analytical workflows.
Every 40 mg vial of Retatrutide supplied by NXT GEN PEPTIDES is HPLC-characterised and independently third-party tested to help ensure purity, consistency and reliability across the extended-format supply.
Store lyophilised at -20 °C. After reconstitution, store at 2–8 °C and use within 28 days.
This product is supplied exclusively for scientific and laboratory research. It is not intended for human or veterinary consumption, administration, diagnosis, treatment or therapeutic use.

Triple agonist research peptide (GLP-1/GIP/glucagon).

Synthetic pentadecapeptide fragment for in-vitro laboratory characterisation.

Synthetic thymosin β4 fragment for in-vitro laboratory characterisation.

Copper tripeptide-1 for in-vitro biochemical characterisation.
This site sells research chemicals for in-vitro laboratory research only. You must be 18+ to enter. A full research-use questionnaire and acknowledgements will be required before you can place an order.
Research use only · Not for human or animal consumption